We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · December 23, 2020

Erlotinib vs Etoposide/Cisplatin With Radiotherapy in Unresectable Stage III EGFR Mutation–Positive NSCLC

International Journal of Radiation Oncology, Biology, Physics

 

Additional Info

Disclosure statements are available on the authors' profiles:

International Journal of Radiation Oncology, Biology, Physics
Erlotinib vs Etoposide/Cisplatin With Radiotherapy in Unresectable Stage III Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: A Multicenter, Randomized, Open-Label, Phase 2 Trial
Int. J. Radiat. Oncol. Biol. Phys 2020 Nov 18;[EPub Ahead of Print], L Xing, G Wu, L Wang, J Li, J Wang, Z Yuan, M Chen, Y Xu, X Fu, Z Zhu, Y Lu, C Han, T Xia, C Xie, G Li, S Ma, B Lu, Q Lin, G Zhu, B Qu, W Zhu, J Yu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading